Study of miR-32 in populations with obesity and non-alcoholic fatty liver disease

Role and mechanism of miR-32 in obesity and non-alcoholic fatty liver

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058163

Enrollment

Unknown

Registered

2022-03-31

Start date

2022-04-01

Completion date

Unknown

Last updated

2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, NAFLD

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Obesity and fatty liver group: (1) Patients with obesity and NAFLD who attended the obesity clinic of the Department of Endocrinology at the First Affiliated Hospital of South China University; (2) Patients who underwent obesity weight reduction surgery at the Department of Gastrointestinal Surgery, The First Affiliated Hospital of South China University; (3) Patients undergoing gallstone gallbladder surgery in the Department of Hepatobiliary Surgery of the First Affiliated Hospital of South China University; (4) 18 years old = 28 kg/m2 according to WHO criteria; (6) Meeting the diagnostic imaging criteria for NAFLD; (7) Those who voluntarily participated in this study and signed the informed consent form. 2. Control group: (1) Medical examiners from the physical examination center of the First Hospital of South China University; (2) Patients with gallstone disease requiring gallbladder surgery for gallstones; (3) 18 years old <= age <= 70 years old, with no restriction on gender; (4) 18.5 kg/m2 <= BMI < 24 kg/m2 according to WHO criteria; (5) Those who voluntarily participated in this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Various autoimmune diseases; 2. Various chronic inflammatory diseases; 3. History of chronic liver and kidney diseases or impaired liver and kidney function; 4. Patients with alcoholic fatty liver, autoimmune liver disease, viral liver disease and drug-induced liver disease; 5. History of tumor; 6. Recent history of infection; 7. Glucocorticoid use in the last 3 months or ongoing; 8. Trauma in the last 3 months; 8. History of heart attack or cerebral infarction in the last 3 months.

Design outcomes

Primary

Measure	Time frame
miR-32;Adipokine;	—

Countries

China

Contacts

Public ContactXiao Xin-Hua

The First Affiliated Hospital of University of South China

xinhua0102@163.com+86 19976759198

Outcome results